Recent advances in chemokine-directed strategies to improve CAR-T cell infiltration into solid tumors.
Engineering CAR-T cells to better follow chemical signals in the tumor microenvironment offers multiple promising molecular targets to extend immunotherapy beyond blood cancers.
This focused review in Int Immunopharmacol systematically covers chemokine/receptor strategies structured by chemokine classification to enhance CAR-T cell infiltration in solid tumors — the major remaining barrier to CAR-T success beyond hematologic malignancies. Multiple axes (CXCR3, CCR2/5/7, CXCL10) with preclinical and early clinical validation are presented as tractable engineering targets.
What the study was
- Study design
- Narrative review
- Population
- Solid tumor patients (preclinical and early clinical CAR-T data)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Immunopharmacology
Why it surfaced
Focused CAR-T chemokine review addressing key translational barrier; Int Immunopharmacol; single author limits breadth; mainly preclinical; relevant to CAR-T watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.